Parallel Advisors’s INmune Bio INMB Stock Holding History

Parallel Advisors’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-100	Closed	-$2K	–	3178
2021 Q3	$2K	Hold	100	–	–	﹤0.01%	2693
2021 Q2	$2K	Hold	100	–	–	﹤0.01%	2573
2021 Q1	$1K	Buy	+100	New	+$1.8K	﹤0.01%	2635

Other funds holding INMB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Parallel Advisors's INMB Position: Q4 2021 in Review

Parallel Advisors sold out of INmune Bio (INMB) in Q4 2021, closing a stake of 100 shares — an estimated $2K sold.

Parallel Advisors first reported a position in INMB in Q1 2021 and held it in 3 quarters. The position peaked at $2K in Q3 2021. 43 funds tracked by Wall St. Rank hold INMB as of Q4 2021.

Parallel Advisors reported no remaining INmune Bio position as of Q4 2021 after selling out during the quarter.
Parallel Advisors sold 100 INmune Bio shares in Q4 2021, an estimated $2K.
Parallel Advisors first reported a position in INmune Bio in Q1 2021 and held it in 3 quarters.
Parallel Advisors's INmune Bio position peaked at $2K in Q3 2021.
43 funds tracked by Wall St. Rank held INmune Bio as of Q4 2021.

Based on Parallel Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.